• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

    2/5/24 8:04:43 AM ET
    $ATRA
    $BCEL
    $BETS
    $BIOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATRA alert in real time by email

    Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) rose sharply in today’s pre-market trading.

    4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.

    4D Molecular Therapeutics shares jumped 20.1% to $21.01 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Chenghe Acquisition Co. (NASDAQ:CHEA) gained 68.1% to $9.23 in pre-market trading after dipping around 46% on Friday.
    • Tritium DCFC Limited (NASDAQ:DCFC) shares jumped 51.9% to $0.1990 in pre-market trading. Tritium DCFC said the company was the top-awarded fast charger manufacturer for the first round of the State of Tennessee’s National Electric Vehicle Infrastructure (NEVI) Formula Program.
    • YanGuFang International Group Co., Ltd. (NASDAQ:YGF) gained 27.4% to $0.7641 in pre-market trading after falling around 19% on Friday.
    • Magic Empire Global Limited (NASDAQ:MEGL) shares gained 21.6% to $0.9841 in pre-market trading.
    • CalAmp Corp. (NASDAQ:CAMP) shares gained 16.8% to $3.61 in pre-market trading after dipping around 14% on Friday. CalAmp recently announced a 1-for-23 reverse stock split.
    • 2U, Inc. (NASDAQ:TWOU) shares gained 16.1% to $ 0.9199 in pre-market trading after declining over 8% on Friday.
    • Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) shares rose 14.8% to $1.55 in pre-market trading.
    • Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares rose 14.7% to $1.40 in pre-market trading after surging 47% on Friday.
    • Griid Infrastructure Inc. (NASDAQ:GRDI) shares rose 14.4% to $2.38 in pre-market trading after dipping more than 50% on Friday.

    Losers

    • Cano Health, Inc. (NYSE:CANO) shares dipped 60% to $0.92 in pre-market trading. Cano Health initiated prearranged voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware.
    • DMK Pharmaceuticals Corporation (NASDAQ:DMK) shares fell 44.4% to $0.2889 in pre-market trading. The company filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.
    • NanoString Technologies, Inc. (NASDAQ:NSTG) fell 37% to $0.2951. The company initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware.
    • Bit Brother Limited (NASDAQ:BETS) shares fell 23% to $2.31 in pre-market trading. Bit Brother received delisting notice from the Nasdaq.
    • NexImmune, Inc. (NASDAQ:NEXI) declined 12% to $11.09 in pre-market trading. NexImmune announced a $3.67 million registered direct offering priced at-the-market under Nasdaq rules.
    • SCWorx Corp. (NASDAQ:WORX) fell 10.6% to $1.10 in pre-market trading after dipping 8% on Friday.
    • Atreca, Inc. (NASDAQ:BCEL) shares declined 9.5% to $0.2489 in pre-market trading.
    • Biora Therapeutics, Inc. (NASDAQ:BIOR) shares fell 9.4% to $0.85 in pre-market trading.
    • CCSC Technology International Holdings Limited (NASDAQ:CCTG) shares dipped 8.7% to $4.72 in pre-market trading after surging 32% on Friday.
    • Banco Santander, S.A. (NYSE:SAN) shares declined 6.9% to $3.89 in pre-market trading. , Iranian entities reportedly used accounts at Lloyds Banking Group and Banco Santander to evade U.S. sanctions.

     

    Now Read This: McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday

     

    Get the next $ATRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRA
    $BCEL
    $BETS
    $BIOR

    CompanyDatePrice TargetRatingAnalyst
    Banco Santander S.A. Sponsored ADR (Spain)
    $SAN
    2/23/2026Sector Perform → Outperform
    RBC Capital Mkts
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Banco Santander S.A. Sponsored ADR (Spain)
    $SAN
    1/13/2026Hold → Buy
    Kepler
    4D Molecular Therapeutics Inc.
    $FDMT
    11/7/2025Underweight → Equal-Weight
    Morgan Stanley
    CAMP4 Therapeutics Corporation
    $CAMP
    10/2/2025$7.00Overweight
    Cantor Fitzgerald
    CAMP4 Therapeutics Corporation
    $CAMP
    9/16/2025Overweight → Neutral
    Analyst
    Banco Santander S.A. Sponsored ADR (Spain)
    $SAN
    6/4/2025Buy
    Citigroup
    More analyst ratings

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/15/25 8:12:20 PM ET
    $CAMP

    Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:59:09 PM ET
    $CAMP

    Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:48:30 PM ET
    $CAMP

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner Pierre Fabre Pharmaceuticals (PFP) has submitted a request to the FDA for a Type A meeting. Pierre Fabre Pharmaceuticals, in partnership with Atara, submitted a briefing book to the FDA addressing the points from the Complete Response Letter dated January 9, 2026, providing additional context and clarification that the ALLELE study was adequate, well-controlled, and sufficient to support the tabelecleucel (tab-cel) Biologics

    3/3/26 8:05:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

    Encouraging data for CAD-1005 in Phase 2 HIT Study  EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders, today provided additional perspectives on development opportunities following its recent pipeline expansion with the addition of 12-LOX inhibitors. As previously announced, Cadrenal recently acquired a portfolio of selective 12-LOX inhibitors, including oral candidates. Encouraging recent data from a bli

    3/2/26 8:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

    Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results from a Phase 2 trial evaluating CAD-1005 (formerly VLX-1005) in patients with heparin-induced thrombocytopenia (HIT), a severe pro-thrombotic reaction to heparin, the most commonly used parenteral anticoagulant

    2/24/26 8:30:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $BCEL
    $BETS
    $BIOR
    SEC Filings

    View All

    SEC Form F-3ASR filed by Banco Santander S.A. Sponsored ADR (Spain)

    F-3ASR - Banco Santander, S.A. (0000891478) (Filer)

    3/4/26 6:01:58 AM ET
    $SAN
    Commercial Banks
    Finance

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    3/3/26 8:30:25 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form IRANNOTICE filed by Banco Santander S.A. Sponsored ADR (Spain)

    IRANNOTICE - Banco Santander, S.A. (0000891478) (Filer)

    2/27/26 4:06:59 PM ET
    $SAN
    Commercial Banks
    Finance

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Banco Santander upgraded by RBC Capital Mkts

    RBC Capital Mkts upgraded Banco Santander from Sector Perform to Outperform

    2/23/26 8:28:41 AM ET
    $SAN
    Commercial Banks
    Finance

    Barclays resumed coverage on 4D Molecular Therapeutics with a new price target

    Barclays resumed coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $33.00

    1/28/26 7:14:57 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd sold $489,019 worth of shares (80,554 units at $6.07) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    1/14/26 9:16:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Sblendorio Glenn

    4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

    1/7/26 9:12:50 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sblendorio Glenn

    3 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

    1/7/26 9:10:20 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Leadership Updates

    Live Leadership Updates

    View All

    Babcock & Wilcox Enterprises, Inc. Appoints Dr. Homaira Akbari (Ph.D.) to Board of Directors

    Babcock & Wilcox Enterprises, Inc. (B&W) (NYSE:BW) announced today that Dr. Homaira Akbari (Ph.D.) has been appointed to its Board of Directors, bringing the total to seven members. Dr. Akbari has served on the Board of Directors of over 25 public and private companies, including Veolia Group, a global leader in waste to energy, environmentals and hazardous waste facilities, and Banco Santander (NYSE:SAN). Dr. Akbari brings extensive international leadership experience across medium and large technology companies, including in the energy and finance sectors. She has held senior management roles in Fortune 1000 companies including Microsoft, Thales and Liberty Media, and served as member

    1/27/26 4:30:00 PM ET
    $BW
    $SAN
    Building Products
    Industrials
    Commercial Banks
    Finance

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/15/24 5:05:27 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Financials

    Live finance-specific insights

    View All

    Webster Financial Corporation Enters Into Merger Agreement With Banco Santander, S.A. for $12.3 Billion

    Creates Top Ten Retail and Commercial Bank by Assets Nationwide Establishes Top Five Bank by Deposits in the Northeast Transaction Provides Compelling Value for Webster Stockholders Webster Financial Corporation (NYSE:WBS), the holding company for Webster Bank, N.A., today announced the signing of a definitive agreement under which Banco Santander, S.A. ("Santander") (NYSE:SAN, Madrid: SAN)) will acquire Webster in a cash-and-stock transaction. Under the terms of the agreement, Webster stockholders will receive $48.75 in cash and 2.0548 Santander American Depository Shares for each Webster common share. Based on Santander's closing stock price on Monday, February 2, 2026, the trans

    2/3/26 1:38:00 PM ET
    $SAN
    $WBS
    Commercial Banks
    Finance
    Major Banks

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care